Novel targeted agents for lung cancer

Clinical Lung Cancer

Volumn 10, Issue SUPPL.1, 2009, Pages

  West, Howard ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

Belagenpumatucel L; Figitumumab; Heat shock protein 90; Immunotherapy; Insulin like growth factor receptor; L BLP25; MAGE A3; Talactoferrin alfa; Vaccine therapy

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN; L BLP25; L-BLP25; LACTOFERRIN; MAGEA3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MUC1 PROTEIN, HUMAN; MUCIN 1; RECOMBINANT PROTEIN; SOMATOMEDIN C RECEPTOR; TALACTOFERRIN ALFA; TUMOR ANTIGEN; TUMOR PROTEIN;

DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; REVIEW;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; LACTOFERRIN; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MUCIN-1; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS;

EID: 67449091974     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2009.s.007     Document Type: Article

References (45)

1. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007; 13:s4652-4.
2. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23:6674-81. (Pubitemid 46190262)
3. Clinicaltrials.gov [Web site]. Cancer vaccine study for unresectable stage III non-small cell lung cancer. Available at: http://www.clinicaltrials. gov/ct/show/NCT00409188?order=1. Accessed: January 14, 2009.
4. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007; 25(suppl 2):B61-71. (Pubitemid 47488551)
5. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):398s (Abstract 7554).
6. Clinicaltrials.gov [Web site]. GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer. Available at:http://www.clinicaltrials.gov/ct2/show/NCT00480025?term= GSK1572932A&rank=2. Accessed: January 14, 2009.
7. Gonzalez G, Crombet T, Catala M, et al. A novel cancer vaccine composed of humanrecombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9:431-5. (Pubitemid 28273037)
8. Vinageras EN, de la Torre A, Rodriguez MO, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:1452-8.
9. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel- L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24:4721-30. (Pubitemid 46630936)
10. Clinicaltrials.gov [Web site]. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00676507?term=Belagenpumatucel-L&rank=1. Accessed: January 14, 2009.
11. de la Rosa G, Yang D, Tewary P, et al. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol 2008; 180:6868-76.
12. Spadaro M, Caorsi C, Ceruti P, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008; 22:2747-57.
13. Hayes TG, Falchook GF, Varadhachary GR, et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 2006; 24:233-40. (Pubitemid 43723899)
14. Wang Y, Raghunadharao D, Raman G, et al. Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial. J Clin Oncol 2006; 24(18 suppl):387s (Abstract 7095).
15. Parikh PK, Wang Y, Ranade AA, et al. Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial. J Clin Oncol 2007; 25(18 suppl):394s (Abstract 7540).
16. Clinicaltrials.gov [Web site]. Safety and efficacy of talactoferrin in addition to standard chemotherapy in patients with non-small cell lung cancer (FORTIS-C). Available at:http://www.clinicaltrials.gov/ct2/show/NCT00706862? term=talactoferrin&rank=1.Accessed: January 14, 2009.
17. Clinicaltrials.gov [Web site]. Safety and efficacy of talactoferrin in previously treated patients with non-small cell lung cancer (FORTIS-M). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00707304?term= talactoferrin&rank=2. Accessed:January 14, 2009.
18. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-18. (Pubitemid 38868620)
19. Karamouzis MV, Papavassiliou AG. The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med 2006; 12:595-602. (Pubitemid 44780198)
20. Spitz MR, Barnett MJ, Goodman GE, et al. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 2002; 11:1413-8. (Pubitemid 35340378)
21. London SJ, Yuan JM, Travlos GS, et al. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002; 94:749-54. (Pubitemid 34567959)
22. Yu H, Berkel H. Insulin-like growth factors and cancer. J La State Med Soc 1999; 151:218-23.
23. Haluska P, Shaw H, Batzel GN, et al. Phase I dose escalation study of the anti-IGF- 1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. J Clin Oncol 2007; 25(18 suppl):444s (Abstract 3586).
24. Karp DD, Paz-Ares LG, Novello S, et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 2008; 26(15 suppl):427s (Abstract 8015).
25. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-50. (Pubitemid 350086476)
26. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. (Pubitemid 44917502)
27. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008 26:(15 suppl)426s (Abstract 8011).
28. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51.
29. Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7:389-94. (Pubitemid 44043548)
30. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-44. (Pubitemid 41058345)
31. Clinicaltrials.gov [Web site]. Carboplatin and paclitaxel with or without CP-751, 871 (an IGF-1R inhibitor) for advanced NSCLC of squamous, large cell and adenosquamous carcinoma histology. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00596830?term=CP-751%2C871&rank=9. Accessed: January 14, 2009.
32. Clinicaltrials.gov [Web site]. Study of CP-751,871 in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced non-small cell lung cancer. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00560573?term=CP-751%2C871&rank=1. Accessed: January 14, 2009.
33. Clinicaltrials.gov [Web site]. Trial of CP-751, 871 and erlotinib in refractory lung cancer (NSCLC). Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00673049?term=CP-751%2C871&rank=2. Accessed: January 14, 2009.
34. Jones HE, Gee JM, Hutcheson IR, et al. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006; 13(suppl 1):S45-51. (Pubitemid 46219248)
35. Coppola D, Ferber A, Miura M, et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994; 14:4588-95. (Pubitemid 24196808)
36. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-1 receptor signaling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11:1-22.
37. Jones HE, Gee JM, Hutcheson IR, et al. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006; 13(suppl 1):S45-51. (Pubitemid 46219248)
38. Chakravati A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastome cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62:200-7. (Pubitemid 34074005)
39. Liu B, Fang M, Lu Y, et al. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 2001; 20:1913-22. (Pubitemid 32458701)
40. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004; 3:1021-30. (Pubitemid 39199597)
41. Whitesell L, Minnaugh EG, De Costa B et al. Inhibition of heat shock protein HSP90- pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. PNAS USA 1994; 91:8324-8.
42. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3:377-83. (Pubitemid 37128324)
43. Infinity Pharmaceuticals [press release]. Infinity and MedImmune present preliminary phase 1 data demonstrating biological activity of IPI-504, a novel Hsp90 inhibitor, in advanced non-small cell lung cancer. Available at: http://investor.ipi.com/releasedetail. cfm?ReleaseID=271272. Accessed: January 14, 2009.
44. Shimamura T, Lowell AM, Engelman JA, et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005; 65:6401-8. (Pubitemid 40994428)
45. Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFRT790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008; 68:5827-38.